Brought to you by 
Endo launches unsolicited bid for Salix; withdraws offer
10 Sep 2020
Executive Summary
Endo International PLC launched an unsolicited proposal to acquire gastrointestinal specialist Salix Pharmaceuticals Ltd. for a combination of 1.4607 Endo common shares and $45.00 in cash per Salix share, which would value the deal at $11bn ($171.81 for each Salix share).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Endo launches unsolicited bid for Salix; withdraws offer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice